{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T12:17:04Z","timestamp":1789301824830,"version":"build-2803163510"},"reference-count":48,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T00:00:00Z","timestamp":1655596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Macrophage activation syndrome (MAS), a severe complication of systemic adult\u2010onset Still\u2019s disease (AOSD), has been reported to occur during interleukin\u20106 (IL\u20106) inhibitor treatment. However, predictors for MAS development are unknown. Therefore, this study investigated predictive features for MAS development after starting IL\u20106 inhibitor treatment in systemic AOSD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In a single\u2010center retrospective study involving systemic AOSD patients who were refractory to high\u2010dose glucocorticoids with immunosuppressants and started IL\u20106 inhibitor treatment between April 2008 and March 2020, we compared the baseline clinical features between patients who developed AOSD flare with MAS features (MAS group) and those who did not (non\u2010MAS group) during IL\u20106 inhibitor treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Only tocilizumab was used as an IL\u20106 inhibitor. Six of 14 refractory systemic AOSD patients developed AOSD flares with MAS features during tocilizumab treatment, including 4 who developed them shortly after initiation. The MAS group had significantly lower neutrophil counts, fibrinogen, and higher IL\u201018\/C\u2010reactive protein (CRP) ratio at starting tocilizumab (baseline) than the non\u2010MAS group. Before starting tocilizumab, neutrophil counts were trending downward and upward in the MAS and non\u2010MAS groups, respectively, with significant differences in changes. Receiver operating characteristic analysis showed that baseline neutrophil counts and fibrinogen and their changes before tocilizumab treatment and baseline IL\u201018\/CRP ratio had significant discriminatory abilities for subsequent MAS development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We identified baseline laboratory features associated with MAS development after initiating an IL\u20106 inhibitor in refractory systemic AOSD patients. These features may reflect the suppression of IL\u20106 signaling, and further suppression of IL\u20106 signaling might trigger early\u2010onset MAS.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.14371","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T06:03:30Z","timestamp":1655705010000},"page":"1003-1012","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult\u2010onset Still\u2019s disease receiving interleukin\u20106 inhibitor treatment"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-2611","authenticated-orcid":false,"given":"Taio","family":"Naniwa","sequence":"first","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Nagoya City University Hospital  Nagoya Japan"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0899-9328","authenticated-orcid":false,"given":"Toru","family":"Yamabe","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Nagoya City University Hospital  Nagoya Japan"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shin\u2010ichiro","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Seirei Hamamatsu General Hospital  Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5426-0420","authenticated-orcid":false,"given":"Koji","family":"Uehara","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Nagoya City University Hospital  Nagoya Japan"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-1257","authenticated-orcid":false,"given":"Shin\u2010ya","family":"Tamechika","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Nagoya City University Hospital  Nagoya Japan"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-8670","authenticated-orcid":false,"given":"Shinji","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Nagoya City University Hospital  Nagoya Japan"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Isogai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine Nagoya City University Hospital  Nagoya Japan"},{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-0974","authenticated-orcid":false,"given":"Junichi","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"},{"name":"Department of Rheumatology Toyokawa City Hospital  Toyokawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.30.2.121"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0081-x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000381996.69261.71"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.046904"},{"key":"e_1_2_8_6_1","first-page":"396","article-title":"Elevated serum interleukin 6, interferon\u2010gamma, and tumor necrosis factor\u2010alpha levels in patients with adult Still\u2019s disease","volume":"25","author":"Hoshino T","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_8_7_1","first-page":"653","article-title":"Interleukin 6: a possible marker of disease activity in adult onset Still\u2019s disease","volume":"14","author":"Scheinberg MA","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.11.046"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213920"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2174"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140288"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23277"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-010-0348-9"},{"key":"e_1_2_8_14_1","first-page":"923497","article-title":"Successful use of higher\u2010dose etanercept for multirefractory systemic flare of adult\u2010onset Still\u2019s disease with liver failure with no response to tocilizumab therapy","volume":"2013","author":"Naniwa T","year":"2013","journal-title":"Case Rep Rheumatol"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.899178"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2016.1221875"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2020.1818961"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2021.1899565"},{"key":"e_1_2_8_19_1","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi M","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39332"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38802"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000161"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199103000-00004"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215211"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216286"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2004.03.023"},{"key":"e_1_2_8_29_1","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still\u2019s disease","volume":"31","author":"Chen DY","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130575"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719544"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750114"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.11.025"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.1.108.108"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(89)80476-4"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080930"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu035"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.004"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2720"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2005.25.407"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40176"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.1.113.113"},{"key":"e_1_2_8_43_1","first-page":"329","article-title":"Infliximab in the treatment of adult Still\u2019s disease refractory to conventional therapy","volume":"19","author":"Cavagna L","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"e_1_2_8_44_1","first-page":"iii55","article-title":"Successful treatment of a small cohort of patients with adult onset of Still\u2019s disease with infliximab: first experiences","volume":"60","author":"Kraetsch HG","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-003-0775-5"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10231"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024026"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.004"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.14371","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:20:37Z","timestamp":1692793237000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.14371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,19]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/1756-185X.14371"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.14371","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,19]]},"assertion":[{"value":"2022-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}